Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-A445 combinations in previously treated NSCLC
CTR20233070Phase 2Completed
- Sponsor
- BeiGene
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gimistotug in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Sep 2023; status: completed.
02
Drugs
gimistotug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20233070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233070.